EIC Summit and Booster grant awardees

During the EIC Summit 2026, for innovation and interaction with EIC, entrepreneurs and innovations – CEO Peter Olofsson-Sahl, as one of the EIC Booster grant winners, came together for discussion with other EIC Booster grant winners in Brussels on 3-4 June.

Researcher – Felix Sanchez Klose

Inicure is growing! We are happy to announce the recruitment of Felix Sanchez Klose to our research department. Along with his background in cell biology and infection models, Felix brings experience from bio-engineering method development, instrumentation, and programming. As he joins the Inicure team, Felix will be crucial in supporting our development activities in the lab, and Inicure’s progression towards CD nomination. Welcome Felix!

INCATE – Network and Support

INCATE-Logotype

Inicure has been awarded support from the INCATE network (Incubator for Antibacterial Therapies in Europe). Access to advice and the network of partners, including industry and health providers, will truly support and boost our work to combat drug-resistant bacterial infections.

Seal of Excellence – EIC – Transition proposal iCURE

The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated by Inicure and submitted together with our partners at Swansea University, Queen Mary University of London and LIOS received very high ranking in the competitive evaluation process. Although the project was eventually not granted, we are super proud to have received the Seal of Excellence by the European Commission!


Pitching Inicure at GoWest – Nordical capital

Inicure was pitched by CEO Peter Olofsson-Sahl at GoWest – Nordic capital 28-29 January 2026. Inicures approach to combat the threat from AMR received great attention from investors and future partners. So many interesting connections, fruitful discussions, and meetings with old and new friends.

Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2025) – Lyon France

Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of Inicure Peter Olofsson-Sahl presetnerd our lates progress, including lead optimisation running at #ScilifeLAB.

This was a great opportunity to update contacts with some of our future R&D partners, and listen to the support provided by CARB-X, Incate and the ID cluster and the listen to updates on the increasing problem with AMR, lack of effective therapies and urge for novel actions and therapies to combat the progression of the global number One medical threat of increasing antibiotic resistance

Nordic Life Science Days 2025 Göteborg Sweden

Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several of or ker research partners, analysing potential future CRO provides and advisors for CMC, pre-clinical safety and routes to clinical studies as well as initiating relation with seed investors and corporate finance.

Peter Olofsson- Sahl participated in the @GUventure organised pitching event for investors taking place to specially invited investors in innovative life science technologies at Gothia Tower

Lead optimisation support from Scilife DDD

Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at University West, has received support from the national drug discovery platform at Scilife LAB. The lead candidates have shown strong potential, particularly for severe infections like chronic urinary tract and lung infections.With the help of DDD, they will focus on optimizing these compounds to meet industry standards. Bringing them closer to clinical use as a much-needed alternative for life-threatening infections. The current project is going very well and we have alreday treached some very promising improved pre-CD molecules and hope to be able to nominate or CD in mid 2026.